Infection risk remains a prominent clinical concern for patients with multiple myeloma (MM), even with the advent of modern, ...

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring ...

skin, sputum, testes and veins. "The alarming link between [microplastics and nanoplastics] occurrence to human tissue lesions and even cancer has attracted scientists’ attention." The authors ...

Patients with multiple myeloma often develop bone lesions resulting in skeletal-related events (SREs), such as spinal cord compression, vertebral collapse, pathologic fractures and bone pain. Bone ...

On the basis of the data presented from the MM-009 and MM-010 trials, FDA approved lenalidomide for use in combination with dexamethasone in patients with MM who have received one prior therapy ...

The MRC Myeloma IX trialists defined high-risk disease by the presence of multiple adverse FISH lesions combined with ISS II or III. In the Intergroupe Francophone du Myélome experience ...